Watchlist Price Alert

Coherus BioSciences Inc. (CHRS)

NASDAQ: CHRS · Real-Time Price · USD

0.80

0.00 (0.11%)

At close: May 29, 2025, 3:59 PM

0.81

0.67%

After-hours: May 29, 2025, 07:15 PM EDT

0.11% (1D)

Bid	0.76
Market Cap	93.27M
Revenue (ttm)	197.5M
Net Income (ttm)	-130.94M
EPS (ttm)	0.44
PE Ratio (ttm)	1.83
Forward PE	-0.96
Analyst	Buy

Ask	0.82
Volume	556,639
Avg. Volume (20D)	1,872,372
Open	0.80
Previous Close	0.80
Day's Range	0.78 - 0.82
52-Week Range	0.66 - 2.43
Beta	1.01

About CHRS

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CHRS

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CHRS stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

-19.11%

Coherus BioSciences shares are trading lower. The ... Unlock content with Pro Subscription

1 month ago

+16.59%

Coherus BioSciences shares are trading higher after the company announced it completed UDENYCA franchise divestiture.

News

2 weeks ago · seekingalpha.com

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Jodi Sievers - Head, Investor Relations Denny Lanfear - Chief Executive Officer T...

2 weeks ago · zacks.com

Coherus BioSciences (CHRS) Reports Q1 Loss, Lags Revenue Estimates

Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago.

1 month ago · seekingalpha.com

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic hep...

2 months ago · seekingalpha.com

Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript

Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaok...